Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

1,002 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
CCR8-targeted specific depletion of clonally expanded Treg cells in tumor tissues evokes potent tumor immunity with long-lasting memory.
Kidani Y, Nogami W, Yasumizu Y, Kawashima A, Tanaka A, Sonoda Y, Tona Y, Nashiki K, Matsumoto R, Hagiwara M, Osaki M, Dohi K, Kanazawa T, Ueyama A, Yoshikawa M, Yoshida T, Matsumoto M, Hojo K, Shinonome S, Yoshida H, Hirata M, Haruna M, Nakamura Y, Motooka D, Okuzaki D, Sugiyama Y, Kinoshita M, Okuno T, Kato T, Hatano K, Uemura M, Imamura R, Yokoi K, Tanemura A, Shintani Y, Kimura T, Nonomura N, Wada H, Mori M, Doki Y, Ohkura N, Sakaguchi S. Kidani Y, et al. Among authors: kanazawa t. Proc Natl Acad Sci U S A. 2022 Feb 15;119(7):e2114282119. doi: 10.1073/pnas.2114282119. Proc Natl Acad Sci U S A. 2022. PMID: 35140181 Free PMC article.
NY-ESO-1 Protein Cancer Vaccine With Poly-ICLC and OK-432: Rapid and Strong Induction of NY-ESO-1-specific Immune Responses by Poly-ICLC.
Takeoka T, Nagase H, Kurose K, Ohue Y, Yamasaki M, Takiguchi S, Sato E, Isobe M, Kanazawa T, Matsumoto M, Iwahori K, Kawashima A, Morimoto-Okazawa A, Nishikawa H, Oka M, Pan L, Venhaus R, Nakayama E, Mori M, Doki Y, Wada H. Takeoka T, et al. Among authors: kanazawa t. J Immunother. 2017 May;40(4):140-147. doi: 10.1097/CJI.0000000000000162. J Immunother. 2017. PMID: 28338507
Immunological classification of renal cell carcinoma patients based on phenotypic analysis of immune check-point molecules.
Kawashima A, Kanazawa T, Goto K, Matsumoto M, Morimoto-Okazawa A, Iwahori K, Ujike T, Nagahara A, Fujita K, Uemura M, Nonomura N, Wada H. Kawashima A, et al. Among authors: kanazawa t. Cancer Immunol Immunother. 2018 Jan;67(1):113-125. doi: 10.1007/s00262-017-2060-5. Epub 2017 Oct 3. Cancer Immunol Immunother. 2018. PMID: 28975380 Free PMC article.
Phenotypic Analysis of Tumor Tissue-Infiltrating Lymphocytes in Tumor Microenvironment of Bladder Cancer and Upper Urinary Tract Carcinoma.
Kawashima A, Kanazawa T, Jingushi K, Kato T, Ujike T, Nagahara A, Fujita K, Morimoto-Okazawa A, Iwahori K, Uemura M, Imamura R, Wada H, Nonomura N. Kawashima A, et al. Among authors: kanazawa t. Clin Genitourin Cancer. 2019 Apr;17(2):114-124. doi: 10.1016/j.clgc.2018.11.004. Epub 2018 Nov 17. Clin Genitourin Cancer. 2019. PMID: 30555025
Clinical importance of the expression of CD4+CD8+ T cells in renal cell carcinoma.
Nishida K, Kawashima A, Kanazawa T, Kidani Y, Yoshida T, Hirata M, Yamamoto K, Yamamoto Y, Sawada M, Kato R, Kato T, Hatano K, Ujike T, Fujita K, Uemura M, Morimoto-Okazawa A, Iwahori K, Yamasaki M, Ohkura N, Sakaguchi S, Nonomura N, Doki Y, Wada H. Nishida K, et al. Among authors: kanazawa t. Int Immunol. 2020 May 8;32(5):347-357. doi: 10.1093/intimm/dxaa004. Int Immunol. 2020. PMID: 31950169
Docetaxel Upregulates HMGB1 Levels in Non-small Cell Lung Cancer.
Haruna M, Hirata M, Iwahori K, Kanazawa T, Yamamoto Y, Goto K, Kawashima A, Morimoto-Okazawa A, Funaki S, Shintani Y, Kumanogoh A, Wada H. Haruna M, et al. Among authors: kanazawa t. Biol Pharm Bull. 2020;43(3):399-403. doi: 10.1248/bpb.b19-00702. Biol Pharm Bull. 2020. PMID: 32115500 Free article.
Tumour grade significantly correlates with total dysfunction of tumour tissue-infiltrating lymphocytes in renal cell carcinoma.
Kawashima A, Kanazawa T, Kidani Y, Yoshida T, Hirata M, Nishida K, Nojima S, Yamamoto Y, Kato T, Hatano K, Ujike T, Nagahara A, Fujita K, Morimoto-Okazawa A, Iwahori K, Uemura M, Imamura R, Ohkura N, Morii E, Sakaguchi S, Wada H, Nonomura N. Kawashima A, et al. Among authors: kanazawa t. Sci Rep. 2020 Apr 10;10(1):6220. doi: 10.1038/s41598-020-63060-1. Sci Rep. 2020. PMID: 32277125 Free PMC article.
Circulating extracellular vesicles carrying Firmicutes reflective of the local immune status may predict clinical response to pembrolizumab in urothelial carcinoma patients.
Jingushi K, Kawashima A, Saito T, Kanazawa T, Motooka D, Kimura T, Mita M, Yamamoto A, Uemura T, Yamamichi G, Okada K, Tomiyama E, Koh Y, Matsushita M, Kato T, Hatano K, Uemura M, Tsujikawa K, Wada H, Nonomura N. Jingushi K, et al. Among authors: kanazawa t. Cancer Immunol Immunother. 2022 Dec;71(12):2999-3011. doi: 10.1007/s00262-022-03213-5. Epub 2022 May 22. Cancer Immunol Immunother. 2022. PMID: 35598195 Free PMC article.
Discovery of imidazo[1,2-b]pyridazine derivatives: selective and orally available Mps1 (TTK) kinase inhibitors exhibiting remarkable antiproliferative activity.
Kusakabe K, Ide N, Daigo Y, Itoh T, Yamamoto T, Hashizume H, Nozu K, Yoshida H, Tadano G, Tagashira S, Higashino K, Okano Y, Sato Y, Inoue M, Iguchi M, Kanazawa T, Ishioka Y, Dohi K, Kido Y, Sakamoto S, Ando S, Maeda M, Higaki M, Baba Y, Nakamura Y. Kusakabe K, et al. Among authors: kanazawa t. J Med Chem. 2015 Feb 26;58(4):1760-75. doi: 10.1021/jm501599u. Epub 2015 Feb 10. J Med Chem. 2015. PMID: 25625617
1,002 results